首页>投融资
Cogent Biosciences
上市后再融资
Cogent Biosciences, Inc.成立于特拉华州。该公司是一家生物技术公司，致力于开发针对遗传疾病的精准疗法。Cogent最先进的产品PLX9486是一种高度选择性的酪氨酸激酶抑制剂，旨在有效抑制KIT D816V突变以及KIT外显子17中的其他突变。KITD816V会引发罕见的严重疾病，称为系统性肥大细胞增多症。
基本信息
-
公司全称Cogent Biosciences Inc
-
类型癌症疗法开发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址275 Wyman Street 3rd Floor Waltham Massachusetts 02451
-
联系电话1-617-9455576
-
邮箱info@cogentbio.com
-
成立时间2014-01-01
投融资
-
2024-02-14上市后再融资2.25亿美元Commodore CapitalRedmile GroupJanus HealthAdage Capital Partners LPVenrock CapitalDeerfieldPerceptive Advisors
-
2023-06-09增发1.5亿美元未透露
-
2022-06-16增发1.73亿美元未透露
-
2020-12-02上市7000万美元未透露
-
2018-03-29上市6439.32万美元未透露
-
2017-03-05债权融资1500万美元Square 1 Bank
-
2015-06-11B轮6500万美元NLVPF-Prime CapitalJennison Associates诺和诺德Sabby Management赛诺菲Sectoral Asset ManagementWellington Management
-
2014-10-21A轮1200万美元Atlas VentureF-Prime Capital赛诺菲
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息